This study comprises 3 stages:
1. Collection of tumor and blood samples. 2. Creation of organoid models based on tumor samples. 3. Development of functional tests to predict clinical response to treatment.
Patient aged 18 years or more
Patient with histologically confirmed, localized endometrial cancer, candidate for surgical treatment.
A high-grade endometrioid histological type and/or
P53 mutation and/or
Other active cancer less than 6 months old (with the exception of treated basal cell carcinoma of the skin).
Patient deprived of liberty, under guardianship, or subject to a legal protection measure, or unable to express consent.
Patient with localized endometrial cancer
Cohort
Prospective
tumour and blood samples
Other interventionTumour and blood samples
Rate of establishment of exploitable tumor organoid lines
Rate of establishment of tumor organoid lines usable for predictive assays of response to PARP inhibitors.
Click on the lead sponsor to view all of their trials.
